ব্লাড ক্যান্সার (AML leukaemia)
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
কোথায় যেতে হবে
এই trial-এর জন্য ভারতের 11টি hospital-এ রোগী নেওয়া হচ্ছে।
রেজিস্ট্রির সারসংক্ষেপ (টেকনিক্যাল)
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo standard induction therapy, the current standard of care. This study will assess the change in disease activity and adverse events in adult participants with acute myeloid leukemia (AML) being treated with of the combination of azacitidine and venetoclax, in India. The combination of azacitidine and venetoclax is being evaluated in the treatment of acute myeloid leukemia (AML). Participants will receive azacitidine with increasing d…
স্পন্সর: AbbVie
ClinicalTrials.gov-এ NCT07044687
রেজিস্ট্রিতে সর্বশেষ আপডেট 11 Sep 2026 · আমাদের দ্বারা পড়া হয়েছে 20 Oct 2026